AG 881

Drug Profile

AG 881

Alternative Names: AG-881

Latest Information Update: 08 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Feb 2017 Agios completes enrolment in its phase I trial for Haematological malignancies in USA (NCT02492737)
  • 01 Jul 2015 Phase-I clinical trials in Haematological malignancies (Late-stage disease) in USA (PO) (NCT02492737)
  • 01 Jun 2015 Phase-I clinical trials in Glioma (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02481154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top